ContextPrescription drugs are instrumental to managing and preventing chronic disease.
Recent changes in US prescription drug cost sharing could affect access to them …

Untreated attention-deficit/hyperactivity disorder (ADHD) can lead to substantial adverse
social, economic, and emotional outcomes for patients. The effectiveness of current …

Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …

How Patient Cost-Sharing Trends Affect Adherence and Outcomes - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

Attention‐deficit‐hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that
impairs social, academic, and occupational functioning in children, adolescents, and adults …

Objectives: To determine whether patients respond to increased cost sharing by substituting
less expensive alternatives for medications with higher levels of copayments or coinsurance …

Little is known about the global use and cost of medications for attention deficit hyperactivity
disorder (ADHD). Global use of ADHD medications rose threefold from 1993 through 2003 …

As pharmaceutical expenditure continues to rise, third-party payers in most high-income
countries have increasingly shifted the burden of payment for prescription drugs to patients …

Background Managed care organizations use a variety of strategies to reduce the cost and
improve the quality of medication use. The effectiveness of such policies is not well …

Background Growing expenditures on prescription medicines represent a major challenge
to many health systems. Cap and co‐payment policies are intended as an incentive to deter …